WASHINGTON, DC – Dr. Vinay Prasad, the polarizing official who led U.S. vaccine oversight under the Trump administration, has ...

In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

The threat of another influenza pandemic arising from bird-to-human and then human-to-human transmission drives continuing efforts to develop effective vaccines against avian influenza. In the latest ...

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

Vinay Prasad resigns from the FDA after backlash over vaccine restrictions and gene therapy decisions. Political pressure cited in sudden departure.

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...

Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax's H5N1 avian pandemic influenza vaccine candidate demonstrates immunogenicity in preclinical study: Gaithersburg, Maryland Friday, July 25, 2025, 15:00 Hrs [IST] Novavax, ...

Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.